1
|
LaPorte M, Alverez C, Chatterley A, Kovaliov M, Carder EJ, Houghton MJ, Lim C, Miller ER, Samankumara LP, Liang M, Kerrigan K, Yue Z, Li S, Tomaino F, Wang F, Green N, Stott GM, Srivastava A, Chou TF, Wipf P, Huryn DM. Optimization of 1,2,4-Triazole-Based p97 Inhibitors for the Treatment of Cancer. ACS Med Chem Lett 2023; 14:977-985. [PMID: 37465292 PMCID: PMC10351062 DOI: 10.1021/acsmedchemlett.3c00163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 06/14/2023] [Indexed: 07/20/2023] Open
Abstract
The AAA+ ATPase p97 (valosin-containing protein, VCP) is a master regulator of protein homeostasis and therefore represents a novel target for cancer therapy. Starting from a known allosteric inhibitor, NMS-873, we systematically optimized this scaffold, in particular, by applying a benzene-to-acetylene isosteric replacement strategy, specific incorporation of F, and eutomer/distomer identification, which led to compounds that exhibited nanomolar biochemical and cell-based potency. In cellular pharmacodynamic assays, robust effects on biomarkers of p97 inhibition and apoptosis, including increased levels of ubiquitinated proteins, CHOP and cleaved caspase 3, were observed. Compound (R)-29 (UPCDC-30766) represents the most potent allosteric inhibitor of p97 reported to date.
Collapse
Affiliation(s)
- Matthew
G. LaPorte
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Celeste Alverez
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Pharmaceutical Sciences, University of
Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Alexander Chatterley
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Marina Kovaliov
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Evan J. Carder
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Michael J. Houghton
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Chaemin Lim
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Eric R. Miller
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Lalith P. Samankumara
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Mary Liang
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Pharmaceutical Sciences, University of
Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Kaylan Kerrigan
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Zhizhou Yue
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Shan Li
- Division
of Biology and Biological Engineering, California
Institute of Technology, Pasadena, California 91125, United States
| | - Francesca Tomaino
- Leidos
Biomedical Research, Inc., Frederick, Maryland 21702, United States
| | - Feng Wang
- Division
of Biology and Biological Engineering, California
Institute of Technology, Pasadena, California 91125, United States
| | - Neal Green
- Leidos
Biomedical Research, Inc., Frederick, Maryland 21702, United States
| | - Gordon M. Stott
- Leidos
Biomedical Research, Inc., Frederick, Maryland 21702, United States
| | - Apurva Srivastava
- Leidos
Biomedical Research, Inc., Frederick, Maryland 21702, United States
| | - Tsui-Fen Chou
- Division
of Biology and Biological Engineering, California
Institute of Technology, Pasadena, California 91125, United States
| | - Peter Wipf
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Pharmaceutical Sciences, University of
Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| | - Donna M. Huryn
- University
of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
- Department
of Pharmaceutical Sciences, University of
Pittsburgh, Pittsburgh, Pennsylvania 15260, United States
| |
Collapse
|
2
|
LeBlanc AK, Mazcko CN, Fan TM, Vail DM, Flesner BK, Bryan JN, Li S, Wang F, Harris S, Vargas JD, Govindharajulu JP, Jaganathan S, Tomaino F, Srivastava AK, Chou TF, Stott GM, Covey JM, Mroczkowski B, Doroshow JH. Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs. Mol Cancer Ther 2022; 21:1510-1523. [PMID: 35876604 DOI: 10.1158/1535-7163.mct-22-0167] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 05/09/2022] [Accepted: 07/12/2022] [Indexed: 11/16/2022]
Abstract
Pet dogs with naturally-occurring cancers play an important role in studies of cancer biology and drug development. We assessed tolerability, efficacy and pharmacokinetic/pharmacodynamic (PK/PD) relationships with a first-in-class small molecule inhibitor of valosin-containing protein (VCP/p97), CB-5339, administered to 24 tumor-bearing pet dogs. Tumor types assessed included solid malignancies, lymphomas, and multiple myeloma. Through a stepwise dose and schedule escalation schema, we determined the maximum tolerated dose to be 7.5 mg/kg when administered orally on a 4-days on, 3-days off schedule per week for 3 consecutive weeks. Adverse events were minimal and mainly related to the gastrointestinal system. PK/PD data suggests a relationship between exposure and modulation of targets related to induction of the unfolded protein response, but not to tolerability of the agent. An efficacy signal was detected in 33% (2/6) dogs with multiple myeloma, consistent with a mechanism of action relating to induction of proteotoxic stress in a tumor type with abundant protein production. Clinical trials of CB-5339 in humans with acute myelogenous leukemia and multiple myeloma are ongoing.
Collapse
Affiliation(s)
- Amy K LeBlanc
- National Cancer Institute, Bethesda, Maryland, United States
| | | | - Timothy M Fan
- University of Illinois at Urbana-Champaign, Urbana, Illinois, United States
| | - David M Vail
- University of Wisconsin-Madison, Madison, WI, United States
| | - Brian K Flesner
- University of Missouri - College of Veterinary Medicine, Columbia, MO, United States
| | | | - Shan Li
- California Institute of Technology, Pasadena, CA, United States
| | - Feng Wang
- California Institute of Technology, Pasadena, CA, United States
| | - Scott Harris
- Cleave Therapeutics, Inc., San Francisco, CA, United States
| | | | - Jeevan P Govindharajulu
- Frederick National Laboratory of Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States
| | - Soumya Jaganathan
- Frederick National Laboratory of Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States
| | - Francesca Tomaino
- Frederick National Laboratory of Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States
| | - Apurva K Srivastava
- Frederick National Laboratory of Cancer Research, Leidos Biomedical Research, Inc., Frederick, United States
| | - Tsui-Fen Chou
- California Institute of Technology, Pasadena, CA, United States
| | - Gordon M Stott
- Frederick National Laboratory for Cancer Research, Frederick, United States
| | | | | | | |
Collapse
|
3
|
Srivastava AK, Govindharajulu JP, Hollingshead MG, Moore WJ, Tomaino F, Banfield K, Lee T, Olejniczak ET, Sensintaffar J, Millin MD, Parchment RE, Doroshow JH, Fesik S. BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Apurva K. Srivastava
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratories for Cancer Research, Frederick, MD
| | - Jeevan P Govindharajulu
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - William J Moore
- Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Francesca Tomaino
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kelly Banfield
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Taekyu Lee
- Department of Biochemistry, Vanderbilt University, Nashville, TN
| | | | | | | | | | - James H. Doroshow
- Center for Cancer Research, Division of Cancer Treatment and Diagnosis, Bethesda, MD
| | - Stephen Fesik
- Department of Biochemistry, Vanderbilt University, Nashville, TN
| |
Collapse
|
4
|
Srivastava AK, Govindharajulu JP, Hollingshead MG, Stotler H, Wang F, Chou TF, Banfield K, Tomaino F, Stott G, Doroshow JH, Parchment RE. Pharmacodynamics of first-in-class p97 inhibitors that disrupt protein homeostasis in cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e14539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Apurva K. Srivastava
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratories for Cancer Research, Frederick, MD
| | - Jeevan P Govindharajulu
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Howard Stotler
- Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Feng Wang
- David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - Tsui-Fen Chou
- David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - Kelly Banfield
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Francesca Tomaino
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - James H. Doroshow
- Center for Cancer Research, Division of Cancer Treatment and Diagnosis, Bethesda, MD
| | | |
Collapse
|